ChemoCentryx Announces Changes to its Board of Directors
May 31 2022 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced changes to the
composition of its Board of Directors. David E. Wheadon, M.D., has
been elected to the Board as an independent director, and Henry A.
McKinnell, Jr., Ph.D., is retiring from the Board, effective May
26, 2022.
“Dr. David E. Wheadon adds strength and depth to our Board,”
said Thomas J. Schall, Ph.D., President and Chief Executive
Officer of ChemoCentryx. “We look forward to benefitting from
his extensive knowledge in science, clinical, and regulatory
affairs as we seek to expand TAVNEOS’s commercial and clinical
activities, advance our novel small molecule checkpoint inhibitor,
CCX559, for the treatment of cancer, and bring additional pipeline
assets to patients in need. We are also grateful to retiring
Director, Hank McKinnell, for his tenure and contributions to the
Board during an important time in the Company’s history.”
Dr. Wheadon retired from AstraZeneca PLC in 2019 as Senior Vice
President, Global Regulatory Affairs, Patient Safety and Quality
Assurance, a position he had held since 2014. Before joining
AstraZeneca, Dr. Wheadon held a variety of leadership roles in the
healthcare sector, including Executive Vice President, Research and
Advocacy at the Juvenile Diabetes Research Foundation, Senior Vice
President of Global Pharmaceutical Regulatory and Medical Sciences
at Abbott Laboratories, and Senior Vice President of U.S.
Regulatory Affairs at GlaxoSmithKline Laboratories. Dr. Wheadon has
also served as Senior Vice President, Scientific and Regulatory
Affairs at PhRMA, the Washington D.C.-based Pharmaceutical Industry
Research and Manufacturers Association, during which time he
interacted with the Food and Drug Administration (FDA), the
Department of Health and Human Services (HHS), and the National
Institutes of Health (NIH).
Dr. Wheadon holds a M.D. from Johns Hopkins University
School of Medicine and an A.B. in Biology from Harvard University.
He completed his postdoctoral training in Psychiatry at Tufts/New
England Medical Center in Boston, Massachusetts. He currently
serves on the boards of Karuna Therapeutics Inc., Sotera
Health Company, and Vaxart, Inc.
“ChemoCentryx combines a passionate focus on unmet needs with
proven expertise in drug discovery and development,” said Dr.
Wheadon. “I look forward to working closely with my new colleagues
in this rapidly growing organization to bring small molecule
therapeutics to those who need it the most.”
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and
developing new medications for inflammatory and autoimmune diseases
and cancer. ChemoCentryx targets the chemokine and chemoattractant
systems to discover, develop and commercialize orally administered
therapies. In the United States, ChemoCentryx markets TAVNEOS®
(avacopan), the first approved orally administered inhibitor of the
complement 5a receptor as an adjunctive treatment for adult
patients with severe active ANCA-associated vasculitis. TAVNEOS is
also in late-stage clinical development for the treatment of severe
hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G).
Additionally, ChemoCentryx has early-stage drug candidates that
target chemoattractant receptors in other inflammatory and
autoimmune diseases and in cancer. For more information about the
Company visit www.chemocentryx.com.
TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For
more information, please see the Full Prescribing Information and
Medication Guide, available at TAVNEOS.com.
Forward-Looking Statements
ChemoCentryx cautions that statements included in this press
release that are not a description of historical facts are
forward-looking statements. Words such as "may," "could," "will,"
"would," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "intend," "predict," "seek," "contemplate,"
"potential," "continue" or "project" or the negative of these terms
or other comparable terminology are intended to identify
forward-looking statements. These statements include the Company's
statements regarding the achievement of anticipated goals and
milestones, whether the Company's drug candidates, including
CCX559, will be shown to be safe and effective in ongoing or future
clinical trials. The inclusion of forward-looking statements should
not be regarded as a representation by ChemoCentryx that any of its
plans will be achieved. Actual results may differ from those set
forth in this release due to the risks and uncertainties inherent
in the ChemoCentryx business and other risks described in the
Company's filings with the Securities and Exchange Commission
("SEC"). Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and ChemoCentryx undertakes no obligation to revise or
update this news release to reflect events or circumstances after
the date hereof. Further information regarding these and other
risks is included under the heading "Risk Factors" in
ChemoCentryx's periodic reports filed with the SEC, including
ChemoCentryx's Annual Report on Form 10-K filed with the SEC on
March 1, 2022, and its other reports which are available from the
SEC's website (www.sec.gov) and on ChemoCentryx's website
(www.chemocentryx.com) under the heading "Investors." All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.
Contacts:
Investors:Bill Slattery, Jr.Vice President,
Investor Relations& Corporate
Communications650.210.2970bslattery@chemocentryx.com
Media:Stephanie
Tomei408.234.1279media@chemocentryx.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024